A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1) SUCCESSOR-1
Verified

What's the purpose of this trial?

The purpose of this study is to compare the efficacy and safety of CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

This trial is currently open and accepting patients.


What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Participant has documented diagnosis of MM and measurable disease, defined as any of the following:

    • M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or
    • M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP)
    • For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.
  • Participants received 1 to 3 prior lines of antimyeloma therapy.
  • Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.

Exclusion Criteria:

  • Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor.
  • For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
  • Participant has had prior treatment with CC-92480 or pomalidomide.

Other protocol-defined criteria apply.


Additional Trial Information

Phase 3

Enrollment: 760 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Connecticut

Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven

New Haven, CT

Not Yet Accepting

Georgia

University Cancer and Blood Center

Athens, GA

Open and Accepting

Illinois

University of Illinois at Chicago

Chicago, IL

Not Yet Accepting

Iowa

Holden Comprehensive Cancer Center University of Iowa Hospitals and Clinics

Iowa City, IA

Not Yet Accepting

Louisiana

Tulane Cancer Center Tulane University School of Medicine

New Orleans, LA

Not Yet Accepting

Massachusetts

Dana-Farber Cancer Institute

Boston, MA

Not Yet Accepting

Mississippi

Hattiesburg Clinic

Hattiesburg, MS

Open and Accepting

New York

Jonah Cancer Care Center & ECMC

Buffalo, NY

Not Yet Accepting

Northwell Health Monter Cancer Center

Lake Success, NY

Not Yet Accepting

Pennsylvania

WellSpan Health-York Cancer Center

York, PA

Not Yet Accepting

Tennessee

West Cancer Center (East Campus - Germantown) East Campus

Germantown, TN

Open and Accepting

Utah

Utah Cancer Specialists Cancer Center

Salt Lake City, UT

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors